Oncopharmpod
Ruby Trial & Quizartinib Toxicity
- Autor: Vários
- Narrador: Vários
- Editor: Podcast
- Duración: 0:14:29
- Mas informaciones
Informações:
Sinopsis
The Ruby trial leads to an FDA approval for dostarlimab + chemo in advanced/recurrent endometrial cancer, but only dMMR/MSI-H patients. Quizartinib's label and REMS program provide some clear, but concerning, warnings about its toxicity.
